Waltham, MA - April 29, 2015 - Corindus Vascular Robotics [OTCQB: CVRS], a leading developer of precision vascular robotics, announced today that Prof. Dr. Marianne Brodmann, a leading researcher at the Medical University of Graz in Graz, Austria will present data from the CorPath® Robotic-Assisted Peripheral Vascular Intervention Trial during the 37th Charing Cross Conference in London, UK on April 28 - May 1, 2015.
Launched in February of this year, the trial is assessing the safety and effectiveness of the CorPath System in recanalizing lower extremity arterial blockages during peripheral angioplasty procedures. The procedures were performed by Dr. Marianne Brodmann, Dr. Peter Kalmar, Dr. Florian Schmid, and Prof. Dr. Hannes Duetschmann, from the Medical University of Graz.
Dr. Brodmann will present her findings during "Evaluation of a robotic system for femoropopliteal interventions," on Thursday, April 30 at 11:24 a.m.
Developed by Corindus Vascular Robotics, the CorPath System is the first FDA-cleared medical device to bring robotic-assisted precision to coronary angioplasty procedures. The CorPath System is currently indicated in the U.S. for Percutaneous Coronary Intervention (PCI) only. During the procedure, the interventional cardiologist sits in the radiation-shielded interventional cockpit and advances stents and guidewires with millimeter-by-millimeter precision.
For more information about the CorPath System, visit www.corindus.com.
Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."
For additional information, visit www.corindus.com, and follow @CorindusInc.
Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future event
Examples of such statements include statements:
